Kazia Therapeutics announced that paxalisib monotherapy reduced tumor burden by 52% in preclinical models of MSS/pMMR colorectal cancer, a type typically resistant to immunotherapy. When combined with pembrolizumab, tumor reduction improved by an additional 50%. The treatment was well tolerated with no significant toxicity. Kazia plans a Phase 2 clinical trial starting in early 2027 to test paxalisib alone and with pembrolizumab against standard care in this patient group, aiming to offer a new option for the majority of metastatic colorectal cancer patients who currently have limited immunotherapy benefits.
Alphabet CEO Sundar Pichai revealed that the company is facing challenges in rapidly expanding its AI capacity to meet demand. Meanwhile, competitor Anthropic has successfully secured 5 gigawatts of AI computing power, highlighting a significant deve...
The Communication Services Select Sector SPDR Fund (XLC), often assumed to be a telecom income ETF, primarily holds big tech and media companies like Meta and Alphabet, which pay little dividend. Traditional telecom firms like AT&T, Verizon, and Comc...
The AI revolution is boosting demand for skilled trades jobs, with companies like Lowe's, Meta, Nvidia, and others forming a coalition to train 1 million tradespeople by 2035. This effort addresses a U.S. shortage of 2 million skilled workers, which ...
Rocket Lab's stock has fallen over 57% from its peak despite strong revenue growth and a growing backlog, creating a disconnect between performance and market value. Analysts remain bullish, with a consensus price target implying about 77% upside and...
Netlist, a fabless company designing advanced memory modules, is considered a high-risk stock with significant upside potential. Its future value depends on the adoption of its innovative memory technology and the outcomes of ongoing patent litigatio...
